Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17152483 | 0.87 | EPHX1 (0.41) | EPHX1NPC1SMN1; SMN2RAB9AHTT | |
| SCHEMBL15618596 | 0.87 | EPHX1 (0.38) | EPHX1NPC1SMN1; SMN2RAB9AHTT | |
| SCHEMBL5099310 | 0.80 | KDM4E (0.35) | — | |
| SCHEMBL17152289 | 0.78 | OPRK1 (0.34) | POLBNPC1SMN1; SMN2RAB9A | |
| SCHEMBL17152280 | 0.77 | EPHX2 (0.35) | SIGMAR1 | |
| SCHEMBL17152404 | 0.75 | SMN1; SMN2 (0.43) | EPHX1SMN1; SMN2GAAHTR4 | |
| SCHEMBL17152502 | 0.74 | PARP1 (0.41) | NPC1SMN1; SMN2RAB9AHTR4 | |
| SCHEMBL17152226 | 0.74 | ALDH1A1 (0.41) | POLB | |
| SCHEMBL17152590 | 0.73 | MEN1 (0.40) | SIGMAR1HTR4 | |
| SCHEMBL17152152 | 0.73 | MEN1 (0.40) | SIGMAR1HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796793-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20070293477-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2007-12-20 | — | — | US | disclosed |
| EP-1796793-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006029154-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293477-A1 | Novel Compounds | HRH4, TRPV4, TRPC4 | EPHX1 600/4885POLB 4864/4885GNAI3 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.